Morgan Stanley Celldex Therapeutics, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 435,818 shares of CLDX stock, worth $12.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

435,818

Previous 163,992 165.76%

Holding current value

$12.2 Million

Previous $6.07 Million 143.93%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$32.06 - $44.56 $8.71 Million - $12.1 Million	271,826 Added 165.76%	435,818 $14.8 Million
Q2 2024 Oct 17, 2024	SELL	$32.76 - $42.56 $6.95 Million - $9.03 Million	-212,129 Reduced 56.4%	163,992 $6.07 Million
Q2 2024 Aug 14, 2024	SELL	$32.76 - $42.56 $6.95 Million - $9.03 Million	-212,129 Reduced 56.4%	163,992 $6.07 Million
Q1 2024 Oct 17, 2024	BUY	$35.22 - $51.88 $7.47 Million - $11 Million	212,129 Added 129.35%	376,121 $15.8 Million
Q1 2024 Aug 16, 2024	SELL	$35.22 - $51.88 $9.94 Million - $14.6 Million	-282,244 Reduced 42.87%	376,121 $15.8 Million
Q1 2024 May 15, 2024	SELL	$35.22 - $51.88 $9.94 Million - $14.6 Million	-282,244 Reduced 42.87%	376,121 $15.8 Million
Q4 2023 Aug 16, 2024	BUY	$22.61 - $40.65 $11.2 Million - $20.1 Million	494,373 Added 301.46%	658,365 $26.1 Million
Q4 2023 Feb 13, 2024	BUY	$22.61 - $40.65 $3.04 Million - $5.47 Million	134,665 Added 25.71%	658,365 $26.1 Million
Q3 2023 Nov 15, 2023	BUY	$25.45 - $37.46 $9.82 Million - $14.5 Million	385,916 Added 280.09%	523,700 $14.4 Million
Q2 2023 Aug 14, 2023	SELL	$30.29 - $38.28 $10.8 Million - $13.6 Million	-355,261 Reduced 72.05%	137,784 $4.68 Million
Q1 2023 May 15, 2023	BUY	$34.78 - $47.43 $10.1 Million - $13.7 Million	289,356 Added 142.06%	493,045 $17.7 Million
Q4 2022 Feb 14, 2023	BUY	$27.78 - $45.38 $8,500 - $13,886	306 Added 0.15%	203,689 $9.08 Million
Q3 2022 Nov 14, 2022	SELL	$22.7 - $37.57 $6.33 Million - $10.5 Million	-278,644 Reduced 57.81%	203,383 $5.72 Million
Q2 2022 Oct 27, 2022	SELL	$20.5 - $37.33 $11 Million - $20 Million	-536,997 Reduced 52.7%	482,027 $13 Million
Q2 2022 Aug 15, 2022	SELL	$20.5 - $37.33 $11 Million - $20 Million	-536,997 Reduced 52.7%	482,027 $13 Million
Q1 2022 Oct 27, 2022	BUY	$27.64 - $39.32 $14.8 Million - $21.1 Million	536,997 Added 111.4%	1,019,024 $34.7 Million
Q1 2022 May 13, 2022	BUY	$27.64 - $39.32 $19.7 Million - $28 Million	713,091 Added 233.09%	1,019,024 $34.7 Million
Q4 2021 Feb 14, 2022	BUY	$35.68 - $56.27 $4.58 Million - $7.22 Million	128,397 Added 72.32%	305,933 $11.8 Million
Q3 2021 Nov 15, 2021	BUY	$28.95 - $55.99 $5.14 Million - $9.94 Million	177,536 New	177,536 $9.58 Million

Others Institutions Holding CLDX

# of Institutions

207

Shares Held

67.3M

Call Options Held

1.69M

Put Options Held

980K

View Full List

About Celldex Therapeutics, Inc.

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $1.3B
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

More about CLDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account